---

原文標題：

Moderna Warns New Waves of Covid-19 Are Coming
Moderna 警告新一波 Covid-19 即將到來

原文連結：

https://reurl.cc/zezERy

發布時間：

Updated May 28, 2021 9:03 am ET / Original May 28, 2021 8:17 am ET

原文內容：


Moderna scientists and executives laid out their plans to combat new strains
of the virus that causes Covid-19 at a virtual investor event on Thursday,
saying that new waves of the epidemic are on their way.

“As the virus spreads, it is rapidly mutating,” the company’s chief
scientific officer, Melissa Moore, said on the call. “Some of these new
viral strains appear to be even more transmissible than the original strain…
 We already know that some of these new strains are less susceptible to
neutralization by our current vaccine.”

The company said that it tests new variants in the lab against its vaccines,
and is “constantly” making and testing new versions of its vaccine. But it
warned that the process is not instantaneous, and that the company’s agility
is limited by the complexity of the work.

“The shortest time from the detection of a variant of concern to preclinical
immunogenicity readout against a panel of pseudoviruses is approximately 2 to
3 months,” said Guillaume Stewat-Jones, a Moderna (ticker: MRNA) scientist
who works as associate director of antigen design and selection on their
infectious disease team. “And new viral variants are coming — emerging
constantly in real time.”


The company offered an overview of a range of its scientific programs in the
presentation, including discussions on the engineering of its messenger RNA
and the performance of the lipid nanoparticles that enclose the messenger RNA
particles.

Analyst questions at the end of the call, however, focused almost entirely on
its Covid-19 vaccines. That is another sign of the importance the vaccine to
the current valuation of Moderna (ticker: MRNA) shares, as SVB Leerink
analyst Mani Foroohar wrote in a note out Thursday.

In a separate note, Jefferies analyst Michael Yee wrote that the presentation
demonstrated Moderna’s leadership in messenger RNA-based therapeutics.

“[Management] is investing in engineering to ensure they have ‘
differentiated’ mRNA constructs…  and this will be a key ‘moat’ to just
anyone being able to ‘do mRNA,’” Yee wrote.

Moderna shares climbed 2.3% on Thursday, and were down 0.4% on Friday.

Barron’s argued in a feature in late April that Moderna shares had room to
climb, and that Wall Street’s worries over its market value, which at that
time was $67 billion and is now $70.5 billion, were overblown.


Foroohar and Yee are more cautious. Foroohar has an Underperform rating on
Moderna, at a target price of $83, while Yee has a Hold rating and a target
price of $170. Moderna closed at $179.54 on Thursday, and is up 71.9% so far
this year, and more than 220% over the past 12 months.

機翻如下：

Moderna公司的科學家和高管們在週四的一次虛擬投資者活動中闡述了他們對抗導致
Covid-19的病毒新菌株的計畫，並表示新一波的疫情正在到來。



該公司說，它在實驗室中針對其疫苗測試新的變種，並 "不斷" 製造和測試其疫苗的新版
本。但它警告說，這個過程不是即時的，而且公司的敏捷性受到工作複雜性的限制。




該公司在演講中對其一系列科學項目進行了概述，包括討論其信使RNA的工程和包裹信使
RNA顆粒的脂質納米顆粒的性能。

然而，在電話會議結束時，分析師的問題幾乎完全集中在其Covid-19疫苗上。SVB
Leerink的分析師Mani Foroohar在週四發佈的一份說明中寫道，這也是疫苗對Moderna（
股票代碼：MRNA）股票當前估值的重要性的另一個跡象。

傑富瑞分析師Michael Yee在另一份報告中寫道，該報告顯示了Moderna在基於信使RNA的
治療方面的領先地位。

"Yee寫道："[管理層]正在對工程進行投資，以確保他們擁有'差異化'的mRNA構建體
......這將是任何人能夠'做mRNA'的關鍵'護城河'。

Moderna股價在週四攀升了2.3%，週五下跌了0.4%。

巴倫週刊》在4月底的一篇專題報導中認為，Moderna股價還有攀升的空間，華爾街對其市
場價值的擔憂被誇大了，當時的市值是670億美元，現在是705億美元。





心得/評論：

說實在的MRNA已經炒很高了

不過病毒的變異性就擺在那邊

儘管還有很多疑慮

但是目前能夠最快又最有效的應對新型變種病毒的疫苗技術

還是唯一看好mRNA

沒有辦法自己做疫苗的國家

將來勢必要每年捧著幾百億去MRNA公司門口跪著求賣

長多啦長多

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 180.217.37.18 (臺灣)
※ 文章代碼(AID): #1WjDyQSQ (Stock)
※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1622466330.A.71A.html